teladoc tirzepatide Tirzepatide Unlocked: A Practical Guide

10.1161/HYPERTENSIONAHA.123.22022 [DOI] [PMC free article] [PubMed] [Google Scholar] 13

This side effect also appears to be quite rare

The other one is a liraglutide, which is a GLP-1 RA

The landmark SURMOUNT-1 trial demonstrated average weight loss of approximately 20% of body weight over 72 weeks at the highest dose greater than any single-receptor GLP-1 drug

If you are already on liraglutide and achieving good results with tolerable side effects, there may not be a compelling reason to switch

This mainstream acceptance reflects a growing recognition of the complexity of weight management and the importance of a multifaceted approach to achieve sustainable results